Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD -4.33%21 Gross Margin % is 13.04% as of Sep. 2025, which is 39% below its 10-year median of 21.33. GuruFocus rates HKPD with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 116 Medical Distribution companies, Cellyan Biotechnology Co ranks worse than 78.45% on this metric.
Cellyan Biotechnology Co (NAS:HKPD) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Cellyan Biotechnology Co had a gross margin of 13.04% for the quarter that ended in Sep. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Cellyan Biotechnology Co Gross Margin % Related Terms
Cellyan Biotechnology Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cellyan Biotechnology Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co Gross Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Cellyan Biotechnology Co (HKPD) has a Gross Margin % of 13.04% as of Sep. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Cellyan Biotechnology Co and its competitors. This is 39% below median its historical median of 21.33. Over the past decade, Cellyan Biotechnology Co's Gross Margin % has ranged from 8.81 to 21.81. According to the industry distribution chart, Cellyan Biotechnology Co ranks #91 out of 116 companies in the Medical Distribution industry, placing it in the top 78.4%.
Is Cellyan Biotechnology Co's Gross Margin % too high?
Cellyan Biotechnology Co's current Gross Margin % of 13.04% is 39% below median its 10-year median of 21.33. Over the past 10 years, this metric has ranged from a low of 8.81 to a high of 21.81. The Medical Distribution industry median Gross Margin % is 14.90. Cellyan Biotechnology Co's value of 13.04% is 12.5% below this industry median. Based on the distribution chart, Cellyan Biotechnology Co ranks #91 out of 116 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's Gross Margin % compare to COSM and SNYR?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #91 out of 116 companies for Gross Margin %. This places Cellyan Biotechnology Co in the lower half of its industry. The industry median Gross Margin % is 14.90. Cellyan Biotechnology Co's value of 13.04% is 12.5% below this benchmark. Historically, Cellyan Biotechnology Co's own Gross Margin % has ranged from 8.81 to 21.81 over the past decade. While the company's 10-year median is 21.33 vs. the industry median of 14.90, Cellyan Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Distribution company?
The median Gross Margin % among Medical Distribution companies is 14.90, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cellyan Biotechnology Co's current Gross Margin % of 13.04% is 12.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Cellyan Biotechnology Co and its competitors. For the Medical Distribution industry, the median Gross Margin % is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current Gross Margin % is 13.04%, which is 39% below median its own 10-year median of 21.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current Gross Margin % of 13.04%. The current Gross Margin % is 13.04%, which is 39% below median its 10-year median of 21.33 and 12.5% below the Medical Distribution industry median of 14.90. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current Gross Margin % is 13.04% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score
Get the complete analysis for HKPD
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
